Pfm Health Sciences, LP Praxis Precision Medicines, Inc. Transaction History

Pfm Health Sciences, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.87 - $1.71 $24,564 - $48,281	28,235 Added 0.32%	8,919,997 $15.3 Million
Q2 2023 Aug 14, 2023	BUY	$0.83 - $1.18 $5.57 Million - $7.92 Million	6,715,168 Added 308.52%	8,891,762 $10.2 Million
Q1 2023 May 15, 2023	SELL	$0.8 - $4.98 $480,698 - $2.99 Million	-600,873 Reduced 21.63%	2,176,594 $1.76 Million
Q4 2022 Feb 14, 2023	SELL	$1.88 - $36.45 $1.28 Million - $24.8 Million	-681,058 Reduced 19.69%	2,777,467 $6.61 Million
Q3 2022 Nov 14, 2022	BUY	$2.5 - $37.95 $402,945 - $6.12 Million	161,178 Added 4.89%	3,458,525 $7.85 Million
Q2 2022 Aug 15, 2022	BUY	$1.75 - $11.34 $4.26 Million - $27.6 Million	2,432,528 Added 281.28%	3,297,347 $8.08 Million
Q1 2022 May 16, 2022	BUY	$10.21 - $20.29 $2.34 Million - $4.64 Million	228,915 Added 36.0%	864,819 $8.83 Million
Q4 2021 Feb 14, 2022	BUY	$16.76 - $22.99 $3.03 Million - $4.15 Million	180,530 Added 39.64%	635,904 $12.5 Million
Q2 2021 Aug 16, 2021	BUY	$18.28 - $33.05 $8.32 Million - $15.1 Million	455,374 New	455,374 $8.32 Million

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $3.54B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

Stay updated on Pfm Health Sciences, LP with notifications on news.